sponsored
PatientsVille.com Logo

PatientsVille

Menogon Side Effects Poll Results

Our Users Report - Have you experienced Menogon side effects?

14 user poll responses

Loading...

« go back

Menogon Common Side Effects

The most commonly reported Menogon side effects (click to view or check a box to report):

Ovarian Hyperstimulation Syndrome (5)
Ascites (3)
Unevaluable Event (2)
Transmission Of An Infectious Agent Via A Medicina (2)
Petechiae (2)
Nausea (2)
Hepatitis B (2)
Blood Pressure Increased (2)
Abdominal Pain Lower (2)
Blood Creatine Phosphokinase Increased (1)
Abdominal Pain (1)
Anxiety (1)
Asthma (1)
Muscle Tightness (1)
Dizziness (1)
Endometritis (1)
Headache (1)
Hydrometra (1)
Nervousness (1)
Tremor (1)

➢ More


If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Ovarian Hyperstimulation Syndrome (5)
Ascites (3)
Unevaluable Event (2)
Transmission Of An Infectious Agent Via A Medicina (2)
Petechiae (2)
Nausea (2)
Hepatitis B (2)
Blood Pressure Increased (2)
Abdominal Pain Lower (2)
Endometritis (1)
Abdominal Distension (1)
Abdominal Pain (1)
Anxiety (1)
Asthma (1)
Blood Creatine Phosphokinase Increased (1)
Dizziness (1)
Peritoneal Disorder (1)
Headache (1)
Hydrometra (1)
Simple Partial Seizures (1)
Pyrexia (1)
Ovarian Cancer (1)
Nervousness (1)
Muscle Tightness (1)
Tremor (1)

➢ More

sponsored

It is very important to keep track of all side effects and discuss them with your doctor. If you think you may have a medical emergency, call your doctor or 911 immediately.


Most drugs have a large list of nonsevere or mild adverse effects which do not rule out continued usage. These effects depend on individual sensitivity, and can include nausea, dizziness, diarrhea, malaise, vomiting, headache, dermatitis, dry mouth, etc. Some can be considered a form of pseudo-allergic reaction, as not all users experience these effects; many users experience none at all.

Up-to-date List of Menogon Research Studies

Rank Status Study
1 Not yet recruiting Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation
Condition: Egg Donation
Interventions: Drug: Follistim;   Drug: Ganirelix;   Drug: Menotropins;   Drug: Leuprolide;   Procedure: Transvaginal ultrasound guided needle aspiration of oocytes
Outcome Measures: number of mature oocytes recovered and cryopreserved.;   1) #Days of ovarian stimulation to GnRH agonist trigger.;   2) Peak serum estradiol level on day of GnRH agonist trigger;   Number of follicles >15 mm average diameter on day of GnRH agonist trigger
2 Recruiting What is the Best Preparation for Embryo Transfer in Cryo Cycles: a Natural Cycle or Light Hormonal Stimulation?
Condition: Infertility
Intervention: Drug: human menopausal gonadotrophins
Outcome Measures: implantation rate per embryo;   thickness of the endometrium
3 Recruiting An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos
Condition: Infertility
Intervention: Drug: menotropin
Outcome Measures: Incidence of direct cleavage from 1 to 3 and from 2 to 5 cells;   Incidence of uneven blastomeres at the 2 and 4 cell stage;   Incidence of bi- and multinucleation at 2 cell and 4 cell stage;   Incidence of Smooth Endoplasmatic Reticulum at the Metaphase II stage, the Pro Nuclei stage and the 2, 3 and 4 cell stage;   Positive serum human Chorion Gonadotrophin (hCG) rate;   Implantation rate;   Clinical pregnancy rate;   Ongoing pregnancy rate;   Live birth rate
4 Not yet recruiting Comparison of Treatment Modalities in Poor Responders Undergoing IVF
Condition: Poor Responders
Interventions: Drug: Letrozole;   Drug: human menopausal gonadotropin (hMG)
Outcome Measures: Ongoing pregnancy rate;   Cancellation Rate;   Number of oocytes retrieved;   Number of transferable embryos;   Implantation rate;   Clinical pregnancy rate
5 Recruiting Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.
Condition: Infertility
Interventions: Drug: Ganirelix 0.25 mg.;   Drug: Recombinant choriogonadotropin alfa;   Drug: Micronized natural progesterone.
Outcome Measures: Rate of evolutionary gestation in each cycle;   oocytes (MII) rate by patient;   Number of Participants with Adverse Events
6 Unknown  The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.
Condition: Infertility
Intervention: Drug: MENOPUR; GONAL-F
Outcome Measures: Circulatory levels of Estradiol on the day of hCG;   Total number of follicles as well as the numbers of follicles <10mm, 10-14 mm, >14mm day during gonadotrophin treatment and at the end of stimulation prior to hCG injection;   E2 per follicle >14 mm;   Total number of oocytes retrieved;   fertilization rate;   serum hCG > 10 IU/l on day 12-14 after embryo transfer;   implantation rate;   transferable embryos;   Implantation rate;   Clinical pregnancy rate;   Ongoing pregnancy rate;   embryo quality;   Serum; LH, FSH, Androstenedione, Progesterone, hCG and Inhibin-B. Progesterone seven days after ET day;   Intra follicular levels of; endocrine parameters;   Endometrial thickness; hCG day (minus 0-2 days);   Total gonadotrophin dose administered
7 Not yet recruiting Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients
Condition: Infertility
Interventions: Drug: Nimodipine;   Drug: Placebo
Outcome Measures: Delay of LH surge by at least 2 days;   Side effect profile of nimodipine or placebo.
8 Recruiting Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial
Conditions: Infertility;   Poor Ovarian Response
Interventions: Drug: Corifollitropin alfa;   Drug: recombinant FSH;   Drug: Ganirelix;   Drug: hp HMG
Outcome Measures: Ongoing pregnancy;   Clinical pregnancy;   Biochemical pregnancy;   Number of oocytes retrieved
9 Recruiting Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging
Conditions: Infertility;   Ovarian Aging;   Diminished Ovarian Reserve (DOR);   Predicted Poor-responders
Interventions: Drug: Dehydroepiandrosterone;   Drug: Placebo
Outcome Measures: Number of oocytes retrieved and subsequent pregnancy rate;   Oocyte quality (molecular markers);   Aneuploidy rates in the immature oocytes and unfertilized oocytes using microarray technology
10 Recruiting IVF/ICSI Protocols in Poor Responders With Growth Hormone
Condition: Female Infertility Due to Diminished Ovarian Reserve
Intervention: Drug: Growth hormone (Norditropin, Novo nordisk)
Outcome Measure: Numbers of oocytes retrieved and number of fertilized oocytes
11 Recruiting Study of the Cleavage of the Egg in Relation to the Stimulation Treatment
Condition: Female Infertility
Intervention:
Outcome Measures: Time to 2. polar body extrusion in transferred embryos (only Intracellular Sperm Injection);   Time for disappearance of pronuclei in transferred embryos;   Time for first cleavage in transferred embryos;   Time for cleavage to 3-cell embryo and 4-cell embryo in transferred embryos;   Scoring of blastomere even-size, fragmentation and multinucleation at 4-cell stage;   Total dose of gonadotrophin used;   Gonadotrophin dose per oocyte retrieved;   Number of oocytes retrieved;   Number of fertilized and cleaved oocytes;   Number of preembryos with top quality;   Implantation rate;   Ongoing pregnancy rate week 7;   Live birth rate
12 Recruiting Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles
Condition: Infertility/ Failed IVF Cycles
Interventions: Procedure: Endometrial injury by hysteroscopy or pipelle sampling;   Procedure: Proceed to COH directly
Outcome Measures: Live Birth Rate;   Clinical Pregnancy Rate;   Implantation rate;   Biochemical pregnancy rate;   Ectopic pregnancy rate;   Miscarriage rate;   Ongoing pregnancy rate;   Pregnancy complications (preterm birth, placental abnormalities, bleeding throughout pregnancy, pregnancy related hypertensive disorders, IUGR and SGA)
13 Recruiting Addition of Prednisolone and Heparin in Patients Undergoing Controlled Ovarian Hyperstimulation (COH) for In Vitro Fertilization (IVF) With Failed IVF Cycles
Condition: Infertility
Interventions: Drug: Prednisolone and Heparin during COH for IVF;   Drug: COH for IVF
Outcome Measures: live birth rate;   clinical pregnancy rate
14 Recruiting Evaluation of the Role of Follicular Output Rate in the Prediction of Intra Cytoplasmic Sperm Injection in Women With Unexplained Infertility
Conditions: Subfertility;   Assisted Reproduction
Intervention:
Outcome Measures: Clinical pregnancy;   Retrieved oocytes;   Number of embryos;   Quality of embryos
15 Not yet recruiting Evaluation of the Role of Follicular Sensitivity Index in the Prediction of Pregnancy in Women Undergoing ICSI/IVF Without Polycystic Ovarian Syndrome
Conditions: Subfertility;   Assisted Reproduction
Intervention:
Outcome Measures: Clinical pregnancy;   Retrieved oocytes;   Number of embryos;   Quality of embryos
16 Recruiting Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?
Condition: Subfertility
Intervention: Drug: DHEA
Outcome Measures: Clinical pregnancy;   Number of oocytes retrieved;   Number of formed embryos;   Quality of formed embryos
17 Unknown  Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
Condition: Infertility
Interventions: Drug: ganirelix;   Drug: suprefact
Outcome Measures: pregnancy rate;   ovarian stimulation
18 Recruiting RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
Conditions: Breast Cancer;   Infertility
Intervention: Drug: Letrozole
Outcome Measure: percent of mature oocyte yield
19 Recruiting Cabergoline Versus Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS)
Condition: OHSS
Intervention: Procedure: ICSI
Outcome Measures: Rate and degree of OHSS (composite outcome);   Number of oocytes
20 Unknown  Proteomics & Glyco-Proteomic Analysis of Follicular Fluid
Conditions: Polycystic Ovary Syndrome;   Normal Volunteers
Intervention: Drug: IVF Antagonist Protocol
Outcome Measures: Proteomic analysis;   Hormone analysis

Menogon Patient Forum